| Diabetes Mellitus, Non-Insulin-Dependent
Glyxambi vs Mounjaro
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Glyxambi vs Mounjaro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMounjaro has a higher rate of injection site reactions vs Glyxambi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mounjaro but not Glyxambi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Glyxambi
Mounjaro
At A Glance
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
SC injection
Once weekly
GIP/GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.
Contraindications
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO
Adverse Reactions
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration
Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia
Pharmacology
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Mounjaro
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
UnitedHealthcare
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Mounjaro
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Mounjaro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Glyxambi.
$25/momo
Mounjaro Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GlyxambiView full Glyxambi profile
MounjaroView full Mounjaro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.